Compare Stocks: GALT, SVRA, MGTX, and MNKD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GALT Galectin Therapeutics	$3.71 +1.9%	$3.84	$2.03 ▼ $7.13	$239.72M	0.38	257,500 shs	119,182 shs
MGTX MeiraGTx	$9.89 +5.1%	$12.60	$6.62 ▼ $15.35	$903.77M	1.35	1.13 million shs	836,396 shs
MNKD MannKind	$3.19 +5.6%	$3.75	$2.23 ▼ $6.51	$971.06M	1.09	5.77 million shs	3.76 million shs
SVRA Savara	$4.74 -0.4%	$5.26	$3.49 ▼ $7.01	$977.99M	0.2	2.57 million shs	1.69 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GALT Galectin Therapeutics	+1.92%	+1.92%	-0.54%	-11.24%	-28.52%
MGTX MeiraGTx	+5.10%	-5.81%	-22.49%	-20.50%	+21.50%
MNKD MannKind	+5.63%	-6.73%	-10.39%	-20.84%	-39.01%
SVRA Savara	-0.42%	-1.86%	-9.89%	-14.13%	+31.67%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GALT Galectin Therapeutics	$3.71 +1.9%	$3.84	$2.03 ▼ $7.13	$239.72M	0.38	257,500 shs	119,182 shs
MGTX MeiraGTx	$9.89 +5.1%	$12.60	$6.62 ▼ $15.35	$903.77M	1.35	1.13 million shs	836,396 shs
MNKD MannKind	$3.19 +5.6%	$3.75	$2.23 ▼ $6.51	$971.06M	1.09	5.77 million shs	3.76 million shs
SVRA Savara	$4.74 -0.4%	$5.26	$3.49 ▼ $7.01	$977.99M	0.2	2.57 million shs	1.69 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GALT Galectin Therapeutics	+1.92%	+1.92%	-0.54%	-11.24%	-28.52%
MGTX MeiraGTx	+5.10%	-5.81%	-22.49%	-20.50%	+21.50%
MNKD MannKind	+5.63%	-6.73%	-10.39%	-20.84%	-39.01%
SVRA Savara	-0.42%	-1.86%	-9.89%	-14.13%	+31.67%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GALT Galectin Therapeutics	2.00	Hold	$11.00	196.50% Upside
MGTX MeiraGTx	2.78	Moderate Buy	$24.71	149.89% Upside
MNKD MannKind	2.60	Moderate Buy	$7.84	145.89% Upside
SVRA Savara	2.75	Moderate Buy	$10.25	116.24% Upside

Current Analyst Ratings Breakdown

Latest GALT, SVRA, MGTX, and MNKD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	MGTX MeiraGTx	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C) ➝ Hold (C+)
10/7/2026	SVRA Savara	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$10.00
10/7/2026	SVRA Savara	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
10/7/2026	MNKD MannKind	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$6.00 ➝ $5.00
10/7/2026	SVRA Savara	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$12.00
10/5/2026	MNKD MannKind	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
10/2/2026	MNKD MannKind	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D)
9/24/2026	MGTX MeiraGTx	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Neutral	$16.00
9/24/2026	MGTX MeiraGTx	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Neutral	$16.00
9/22/2026	MGTX MeiraGTx	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D-) ➝ Hold (C)
9/14/2026	GALT Galectin Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)

(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.99) per share	N/A
MGTX MeiraGTx	$81.39M	11.67	N/A	N/A	($0.07) per share	-141.29
MNKD MannKind	$348.97M	2.94	$0.07 per share	48.81	($0.17) per share	-18.76
SVRA Savara	N/A	N/A	N/A	N/A	$1.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GALT Galectin Therapeutics	-$30.84M	-$0.43	N/A	N/A	N/A	N/A	N/A	-176.83%	11/13/2026 (Estimated)
MGTX MeiraGTx	-$114.20M	$0.71	13.93	N/A	N/A	19.87%	283.85%	29.39%	11/12/2026 (Estimated)
MNKD MannKind	$5.86M	-$0.13	N/A	319.00	N/A	-11.08%	N/A	-6.31%	11/4/2026 (Estimated)
SVRA Savara	-$118.84M	-$0.58	N/A	N/A	N/A	N/A	-90.28%	-68.95%	11/11/2026 (Estimated)

Latest GALT, SVRA, MGTX, and MNKD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	Q3 2026	GALT Galectin Therapeutics	-$0.05	N/A	N/A	N/A	N/A	N/A
11/12/2026	Q3 2026	MGTX MeiraGTx	-$0.46	N/A	N/A	N/A	$6.95 million	N/A
11/11/2026	Q3 2026	SVRA Savara	-$0.1633	N/A	N/A	N/A	$0.50 million	N/A
11/4/2026	Q3 2026	MNKD MannKind	-$0.0575	N/A	N/A	N/A	$109.49 million	N/A
8/14/2026	Q2 2026	GALT Galectin Therapeutics	-$0.09	-$0.14	-$0.05	-$0.14	N/A	N/A
8/13/2026	Q2 2026	MGTX MeiraGTx	-$0.4583	$1.71	+$2.1683	$1.71	$0.70 million	$321.43 million
8/11/2026	Q2 2026	SVRA Savara	-$0.1413	-$0.16	-$0.0188	-$0.16	$2.00 million	N/A
8/5/2026	Q2 2026	MNKD MannKind	-$0.0075	-$0.01	-$0.0025	-$0.06	$108.08 million	$109.37 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GALT Galectin Therapeutics	N/A	0.10	0.10
MGTX MeiraGTx	0.46	3.76	3.76
MNKD MannKind	N/A	1.72	1.41
SVRA Savara	0.21	10.13	10.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GALT Galectin Therapeutics	11.68%
MGTX MeiraGTx	67.48%
MNKD MannKind	49.55%
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
GALT Galectin Therapeutics	52.60%
MGTX MeiraGTx	7.40%
MNKD MannKind	2.60%
SVRA Savara	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GALT Galectin Therapeutics	9	65.86 million	31.22 million	Optionable
MGTX MeiraGTx	393	96.04 million	88.94 million	Optionable
MNKD MannKind	592	321.54 million	313.18 million	Optionable
SVRA Savara	70	205.46 million	194.57 million	Optionable

GALT, SVRA, MGTX, and MNKD Headlines

Recent News About These Companies

Will Long‑Term Molgramostim Data at CHEST 2026 Change Savara's (SVRA) Autoimmune PAP Narrative?

October 13 at 12:08 PM | finance.yahoo.com

Savara Inc. (SVRA) - What Are Analysts Thinking About This Stock?

October 13 at 4:15 AM | americanbankingnews.com

Savara Inc. (NASDAQ:SVRA) Stock Has Average Target Price of $10.25 According to Analysts

October 13 at 4:13 AM | marketbeat.com

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis ...

October 12, 2026 | joplinglobe.comJ

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026

October 12, 2026 | businesswire.com

JPMorgan starts Savara coverage with USD 12 target for Savara stock

October 8, 2026 | ad-hoc-news.deA

Savara stock gets USD 12 JPMorgan target before FDA date

October 8, 2026 | ad-hoc-news.deA

Savara (NASDAQ:SVRA) Now Covered by Analysts at JPMorgan Chase & Co.

October 8, 2026 | americanbankingnews.com

Savara (NASDAQ:SVRA) Shares Climb 7.2% - Still a Buy?

October 7, 2026 | marketbeat.com

JPMorgan Initiates Savara at Overweight With $12 Price Target

October 7, 2026 | marketscreener.comM

Savara (SVRA) Reiterated at Market Outperform by Citizens on Molbreevi Optimism

October 7, 2026 | streetinsider.com

Savara (NASDAQ:SVRA) Coverage Initiated by Analysts at JPMorgan Chase & Co.

October 7, 2026 | marketbeat.com

Savara stock fell 4.66 percent ahead of the November FDA decision

October 4, 2026 | ad-hoc-news.deA

Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen

October 4, 2026 | marketbeat.com

Savara (NASDAQ:SVRA) Stock Falls 5.4% - Here's Why

October 2, 2026 | marketbeat.com

Bank of America Corp DE Buys 520,356 Shares of Savara Inc. $SVRA

September 30, 2026 | marketbeat.com

Savara (NASDAQ:SVRA) Raised to Hold at Wall Street Zen

September 26, 2026 | marketbeat.com

Savara Awaits FDA Verdict: Will Molbreevi Pass Regulatory Muster?

September 24, 2026 | rttnews.com

Savara Inc. (NASDAQ:SVRA) Given Consensus Rating of "Moderate Buy" by Analysts

September 18, 2026 | marketbeat.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis ...

August 24, 2026 | uk.finance.yahoo.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

August 24, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT, SVRA, MGTX, and MNKD Company Descriptions

Galectin Therapeutics NASDAQ:GALT

$3.71 +0.07 (+1.92%)

As of 10/15/2026 04:00 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

MeiraGTx NASDAQ:MGTX

$9.89 +0.48 (+5.10%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$9.89 0.00 (0.00%)

As of 10/15/2026 07:30 PM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

MannKind NASDAQ:MNKD

$3.19 +0.17 (+5.63%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$3.19 0.00 (0.00%)

As of 10/15/2026 07:30 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Savara NASDAQ:SVRA

$4.74 -0.02 (-0.42%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$4.82 +0.09 (+1.79%)

As of 10/15/2026 07:30 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GALT, SVRA, MGTX, and MNKD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GALT, SVRA, MGTX, and MNKD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GALT, SVRA, MGTX, and MNKD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT, SVRA, MGTX, and MNKD Company Descriptions

Galectin Therapeutics NASDAQ:GALT

MeiraGTx NASDAQ:MGTX

MannKind NASDAQ:MNKD

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GALT, SVRA, MGTX, and MNKD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GALT, SVRA, MGTX, and MNKD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GALT, SVRA, MGTX, and MNKD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT, SVRA, MGTX, and MNKD Company Descriptions

Galectin Therapeutics NASDAQ:GALT

MeiraGTx NASDAQ:MGTX

MannKind NASDAQ:MNKD

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools